🇺🇸 FDA

Company profile · Sponsor

uniQure

uniQure biopharma B.V.

E898CF3 · EMA biotech EU
Pipeline
2
Drugs
0
Patents
0

Quick answer

uniQure (E898CF3) is a biotech company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E898CF3
Exchange EMA
Company type biotech
Headquarters EU

Pipeline (2)

Search pipeline →

  1. A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

    uniQure

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 other active

    1 trial

  2. ifezuntirgene inilparvovec, ifezuntirgene inilparvovec

    uniQure

    Huntington’s Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is uniQure?

uniQure (E898CF3) is a biotech company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does uniQure sponsor?

We track 2 ClinicalTrials.gov-linked programs for uniQure, including A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) and 1 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does uniQure company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.